Idenix Pharmaceuticals (IDIX)

[gofishmarko]

Tyzeka seems likely to get some positive mentions at this upcoming Novartis-sponsored satellite symposium :

http://www.sgg-sgvc-congress.ch/program-en.php

Annual Meeting
SASL Swiss Association for the Study of the Liver
Lausanne, Palais de Beaulieu, 27.-28.September 2007

1230-1330
Seoul
Novartis satellite symposium
Darius Moradpour, Lausanne

1230-1355
Seoul
Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B
Stefan Zeuzem, Frankfurt

1255-1320
Seoul
Roadmap for Management of Patients Receiving Oral Therapy for Chronic Hepatitis B
Nikolai Naoumov, Basel

1320-1330
Seoul
Discussion


This is the PubMed citation for the same paper :

Clin Gastroenterol Hepatol. 2007 Aug;5(8):890-7. Epub 2007 Jul 13

Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B.

Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, Jacobson IM, Lim SG, Naoumov N, Marcellin P, Piratvisuth T, Zoulim F.

Stanford University School of Medicine, Stanford, California.


The authors are many of the same group from Stanford who published the '06 treatment algorithm I mentioned in the post this one is in reply to. Some feel their influence doesn't carry much weight compared to , say , the AASLD guidelines , so even if Tyzeka is mentioned favorably , it might not help much. Still , it couldn't hurt.